Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.

Yasmin A LyonsHenry D ReyesMegan E McDonaldAndreea NewtsonEric DevorDavid P BenderMichael J GoodheartJesus Gonzalez Bosquet

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

Most patients with advanced epithelial ovarian cancer may benefit from primary cytoreductive surgery. Patients treated with neoadjuvant chemotherapy should be those with co-morbidities unfit for surgery.

Keyphrases

neoadjuvant chemotherapy
minimally invasive
coronary artery bypass
locally advanced
lymph node
sentinel lymph node
surgical site infection
squamous cell carcinoma
rectal cancer
emergency department
radiation therapy
coronary artery disease
atrial fibrillation